Diagnóstico molecular de hipercolesterolemia familiar: uma ferramenta importante para a estratificação do risco cardiovascular by Alves, A.C. et al.
Recebido para publicação: Fevereiro de 2010 • Aceite para publicação: Março de 2010
Received for publication: February 2010 • Accepted for publication: March 2010
907
Molecular diagnosis of familial
hypercholesterolemia: an important tool
for cardiovascular risk stratification [59]
AC ALVES
1,2
, AM MEDEIROS
1,2
, V FRANCISCO
1,2
, IM GASPAR
2,3
, Q RATO
5
, M BOURBON
1, 2
1 Grupo de Investigação Cardiovascular, Unidade I&D, DPSDC, Inst.  Nacional de Saúde Dr. Ricardo Jorge, Lisboa;
2 Center for Biodiversity, Functional & Integrative Genomics
3 Departamento de Genética Médica, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, EPE;
4 Serviço de Cardiologia Pediátrica, Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental;
5 Serviço de Cardiologia, Hospital de São Bernardo, Centro Hospitalar de Setúbal, E.P.E.
ABSTRACT
Familial hypercholesterolemia (FH) is
associated with an increased risk of
premature coronary heart disease. Molecular
identification of these patients can reduce
the burden of mortality from cardiovascular
disorders simply by the correct
identification of the disease early in life,
followed by counseling and appropriate
lifestyle modifications, and therapeutic
measures when required. Recent studies
show that, in Portugal, this disease is
severely under-diagnosed. After more than
10 years of research through the Portuguese
FH Study, it is now possible to translate the
original research results into clinical
application.
Aims: The main aims of the present work
were to determine whether clinical
characterization is sufficient to identify
these individuals at high risk of developing
CHD and to evaluate the clinical
applicability of molecular diagnosis for FH.
Methods: All patients described in this
study were recruited for the Portuguese FH
Study. The diagnostic criteria used to select
the index patients were adapted from the
Simon Broome Heart Research Trust. To
analyze the usefulness of the molecular
diagnosis, graphs of total and LDL
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RESUMO
Introdução: A Hipercolesterolemia Familiar
(FH) associa-se a um aumento do risco de
doença coronária prematura. A identificação
molecular dos indivíduos afectados pode
contribuir para a redução da morbi-
mortalidade por doença cardiovascular, já
que permite a correcta identificação da
patologia em idades mais jovens e o
subsequente aconselhamento e a adopção de
um estilo de vida mais saudável, bem como a
introdução de terapêutica farmacológica mais
precocemente se necessário. Estudos
recentes demonstram que em Portugal a FH
encontra-se  sub-diagnosticada. Depois de
mais de 10 anos de investigação no âmbito
do “Estudo Português de Hipercolesterolemia
Familiar” é agora possível fazer a translação
dos resultados de investigação original para a
aplicação clínica.
Objectivo: O principal objectivo deste
trabalho foi determinar se a caracterização
clínica é suficiente para identificar os
indivíduos com Hipercolesterolemia
Familiar e avaliar a aplicabilidade clínica
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cholesterol values by age were constructed
for 622 possible FH patients. The lipid
profile of patients genetically identified as
having FH, before and under medication,
were analyzed to assess whether these
patients were receiving appropriate
treatment. The data are shown separately for
children and adults and for female and male
propositi (index cases and
hypercholesterolemic relatives), both with
and without a detectable mutation in the
LDLR gene.
Results: The Portuguese FH Study has
already genetically identified 404
individuals (171 index patients and 233
relatives) among more than one thousand
individuals sent for study. A total of 78
different mutations in the LDLR gene were
found in 171 index patients, 2 different
mutations were found in the apoB gene of 4
patients and 2 patients had a unique PCSK9
mutation. Statistical analysis revealed that
there are significant differences between
total cholesterol (p<0.001) and apoB
(p=0.026) values in the group of children
(male and female) with and without a
mutation in LDLR. For female children LDL
values were also significantly different
(p<0.001) between subgroups but for male
children this difference did not reach
statistical significance. In adult women
there is a statistically significant difference
for total cholesterol (p=0.049), LDL
cholesterol (p=0.031) and apoB (p=0.003)
values in the subgroups with and without a
LDLR mutation. In adult males there is a
statistical difference for total cholesterol
(p=0.002). LDL cholesterol (p=0.003) and
apoB (p=0.0023) in subgroups with and
without an LDLR mutation. Nevertheless
there was considerable dispersion of values
and individually it is not possible to
distinguish between patients with and
without a mutation in the LDLR gene, based
only on lipid profile. 
Conclusions: By analysis of the clinical data
of 696 possible FH patients, the present
report shows evidence that clinical
characterization is not sufficient to
do diagnóstico molecular da FH.
Material e Métodos: Todos os doentes em
estudo foram recrutados do “Estudo
Portugês de Hipercolesterolemia Familiar”.
Os critérios de diagnóstico utilizados para a
selecção dos casos-índex foram adaptados
do “Simon Broome Heart Research Trust”.
De modo a se analisar a utilidade do
diagnóstico molecular efectuaram-se
gráficos com o colesterol total e LDL dos
622 indivíduos com diagnóstico clínico de
FH.  O perfil lipídico dos doentes
identificados molecularmente com FH,
antes e após tratamento, foi analisado de
modo a se perceber se estavam a receber o
tratamento adequado. Os resultados são
apresentados separadamente para o grupo
das crianças e adultos, propositi mulheres e
homens” (casos-índex e familiares
hipercolesterolémicos), ambos com e sem
mutação no gene LDLR. 
Resultados: O Estudo Português de
Hipercolesterolemia Familiar foi
estabelecido com sucesso em 1999, tendo já
sido identificados geneticamente 404
indivíduos (171 índex e 233 familiares),
entre mais de 1000 indivíduos enviados
para estudo. Foram encontradas 78
mutações diferentes no gene do receptor das
LDL em 171 casos índex, 2 mutações
diferentes na apoB em 4 casos-índex e uma
única mutação no PCSK9 em 2 
casos-índex. Através da análise estatística
verificou-se que existem diferenças
estatisticamente significativas entre o
colesterol total (p<0,001) e a apoB
(p=0,026) no grupo das crianças (mulheres
e homens) com e sem mutação no gene
LDLR. Nas crianças do sexo feminino para
os valores de cLDL existem diferenças
estatisticamente significativas (p<0,001), no
entanto para as crianças do sexo masculino
não se verificam. Nos adultos do sexo
feminino existem diferenças
estatisticamente significativas para os
valores de colesterol total (p= 0,049), cLDL
(p=0,031) e apoB (p=0,003) nos sub-grupos
com e sem mutação no LDLR.  Nos adultos
homens verificou-se existir também
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INTRODUCTION
Familial hypercholesterolemia (FH) is aninherited disorder of cholesterol metabo-
lism. It is associated with increased risk of
premature coronary heart disease (CHD) and
early identification of affected individuals can
increase their life expectancy and quality, by
the early modification of lifestyle and adminis-
tration of appropriate lipid-lowering treat-
ment. There are about 10,000,000 people with
FH worldwide and approximately 85% of
males and 50% of females with FH will suffer
a coronary event before 65 years of age if
appropriate preventive efforts are not imple-
mented (1). 
FH is one of the most common monogenic
disorders, with a heterozygous frequency of
1/500 in most European populations. It is
estimated that Portugal has about 20,000 FH
patients, but this disorder is severely under-
diagnosed in this country, even though there are
clear indications from the World Health
Organization for large-scale screening(2). The
early identification of these individuals is
essential to decrease their elevated cardiovas-
distinguish between patients with genetic or
environmental dyslipidemia, and so
molecular diagnosis is useful in clinical
practice, allowing correct identification of
FH patients and their relatives, and the
early implementation of therapeutic
measures to reduce the elevated
cardiovascular risk of these patients. In
general, molecular diagnosis of FH is
feasible and could be obtained in 1-2
months if the technology is available. In
Portugal the test will be offered to the
population by our Institute at a cost of about
500 euros, like many other genetic tests or
exams such as nuclear magnetic resonance.
Key words
Familial Hypercholesterolemia; Molecular diagnosis;
LDL receptor  gene; Premature coronary heart
disease; Patient prognosis 
diferenças estatisticamente significativas
para os valores de colesterol total (p=
0,002). cLDL (p=0,003) e apoB (p=0,023)
nos sub-grupos com e sem mutação no
LDLR. No entanto quando visto
graficamente estes valores do perfil lipidico
existe uma grande dispersão e não é
possivel distinguir os doentes com ou sem
mutação no gene LDLR.
Conclusões: Pela análise dos dados clínicos
de 696 indivíduos com diagnóstico clínico
de FH o presente estudo demonstrou
evidência de que a caracterização clínica
não é suficiente para distinguir entre
indivíduos com dislipidemia genética e
ambiental. O diagnóstico molecular é
importante e útil para o clínico, permitindo
a identificação correcta dos doentes com FH
e seus familiares, bem como a aplicação
precoce de medidas terapêuticas para a
redução do risco cardiovascular nestes
doentes. O diagnóstico molecular da FH em
Portugal é viável e efectuado em 1-2 meses,
se a tecnologia utilizada estiver disponível.
O teste molecular da FH em Portugal é
efectuado pelo nosso Instituto e tem um
preço aproximado de 500 euros, como
muitos outros testes genéticos ou uma
ressonância magnética nuclear. 
Palavras chave
Hipercolesterolemia familiar; Diagnóstico molecular;
Receptor das LDL; Doença coronária prematura;
prevenção cardiovascular
cular risk. The plasma total cholesterol levels
in heterozygous FH patients are increased
about 2-3 fold compared to normal subjects
and triglycerides are usually within the
normal range. Hypercholesterolemia, the
earliest manifestation of the disease, is
present at birth in virtually all affected
subjects and remains throughout life. The
finding of severe hypercholesterolemia in
children increases the diagnostic probability
within the family since environmental factors
take longer to show their effect. Tendon
xanthomas, CHD and atherosclerosis are
usually detected after the ages of 30-40 years (3),
but the age of onset of these conditions is
dependent on other genetic and/or environmental
factors, so patients carrying the same mutation
may have completely different plasma total
and LDL cholesterol levels. 
FH is caused in the majority of cases by
mutations in the LDLR gene. Mutations in
other genes such as apolipoprotein B and
proprotein convertase serine kexin 9 (PCSK9)
are rare causes of FH. apoB mutations usually
produce a similar, or milder, phenotype to
mutations in the LDLR gene but the few
patients described with PCSK9 mutations
show a very severe phenotype, similar to the
phenotype of FH patients homozygous for
LDLR mutations (4).
FH patients are at high risk of developing
CHD, however recommendations for the general
population do not apply to FH patients (5). For
the general population the European
Cardiology Society recommends that total
cholesterol levels should be below 190 mg/dl
and LDL cholesterol below 115 mg/dl. For
patients at high risk of developing premature
CHD, as is the case of FH patients, the
recommendations are to decrease cholesterol
levels to below 175 mg/dl and LDL cholesterol
to below 100 mg/dl. If these targets cannot be
reached, then an extra effort should be made
to decrease the overall cardiovascular risk by
better management of other risk factors, for
example by the implementation of a healthy
diet with restricted fat intake and other lifestyle
orientations such as physical activity and
tobacco cessation. The NICE recommendations
for management of familial hypercholeste-
rolemia state that at least a 50% reduction in
basal cholesterol levels should be achieved (6)
to decrease the elevated cardiovascular risk of
these patients.
To overcome the problem of how to reach
these targets with FH patients, a panel of
international experts has gathered to prepare
guidelines for the management of these in-
dividuals(5). Patients with a genetic dyslipi-
demia are at greater risk of premature car-
diovascular disorders since they start to
accumulate cholesterol from birth, so the
treatment of these patients has to be different
and more effective than the treatment of an
environmental dyslipidemia. The majority of
FH patients can only achieve the desired total
and LDL cholesterol when a potent statin is
prescribed and usually combination therapy
is necessary(6). Moderate doses of potent
statins in combination with ezetimibe, a
selective cholesterol intestinal absorption
inhibitor, or resins are the first choice for
combination when over 50% LDL cholesterol
reductions are required or when high doses of
statins are not well tolerated (7). However it is
important to note that ezetimibe has not been
proved to also reduce cardiovascular events
and the progression of arteriosclerotic disease
measured by evaluation of intima-media
thickness(8). To decrease mortality from avoid-
able cardiovascular diseases, the interna-
tional panel of experts on FH also highlighted
the importance of detecting subclinical athe-
rosclerosis for cardiovascular risk stratifica-
tion, since treatment of silent vascular disease
may prevent future clinical events (6). A
healthy lifestyle is also important to achieve a
greater reduction in cholesterol levels. FH
patients should have a healthy diet, ideal
body weight, and moderate but daily physical
activity, and should not smoke. Dietary
recommendations apply to children after the
age of 2-3 years (6).
Their physician should also be able to give
lifestyle counseling or should refer patients to
a specialized clinic for inherited cardiovas-
cular disease (ICD) with a medical geneticist.
This specialist provides a detailed exami-910
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LDL receptor (LDLR) gene were found in 171
index patients, 2 different mutations were
found in the apoB gene of 4 patients and 2
patients had a unique PCSK9 mutation (14). In
Portugal the molecular diagnosis of FH has
been funded by research grants from the
Portuguese Cardiology Society and the
Science and Technology Foundation.
The main aim of this project was to determine
whether clinical characterization is sufficient to
identify these individuals at high risk of
developing CHD and to evaluate the clinical
applicability of molecular diagnosis for FH.
METHODS
All patients described in this study were re-
cruited for the Portuguese FH Study as pre-
viously described (9). The diagnostic criteria used
to select the index patients were adapted from
the Simon Broome Heart Research Trust (1, 9).
To analyze the usefulness of molecular
diagnosis, graphs of total and LDL cholesterol
values by age were constructed for 622 possible
FH patients. The lipid profile of patients
genetically identified as having FH, before and
under medication, were analyzed to assess
whether these patients were receiving appro-
priate treatment. The data are shown separately
for children and adults and for female and male
propositi (index cases and hypercholesterolemic
relatives), both with and without a detectable
mutation in the LDLR gene.
Biochemical characterization
The biochemical tests for total cholesterol,
LDL cholesterol, HDL cholesterol, lipoprotein
(a), apolipoprotein AI and apolipoprotein B
were determined as described elsewhere (9).
Analysis of biochemical data
In this study all index and relatives with a
clinical diagnosis of possible FH were
included, in a total of 696 patients. Graphics
were generated using patients’ and relatives’
biochemical data before treatment, to compare
values between possible FH patients (index
cases and relatives), with and without a 911
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nation of the family history with the ability to
confirm diagnosis in the family, and
knowledge and experience in identifying ICD
and genetic syndromes that may have cardiac
involvement. The medical geneticist also has
experience in understanding of the possible
underlying molecular pathology of ICD, the
likely clinical utility of testing, and
interpretation of tests and uncertain results,
providing advice to parents about recurrence,
and family cascade testing.
Once FH patients are identified they need
to start appropriate treatment immediately,
and this treatment has to be continued for the
rest of their lives, as only in this way can their
cardiovascular risk be reduced. 
There are no absolutely predictive clinical
criteria for the diagnosis of FH, and arbitrary
criteria must be used. Some countries have
developed their own criteria for the diagnosis
of FH, including the USA, the Netherlands and
the UK, and other countries use one of these (9).
Some authors argue that fulfillment of the
clinical criteria is sufficient to identify a FH
patient (10), but lately the need to perform
molecular diagnosis has been put forward as
the only way to correctly identify these patients
(11). The high cost of the genetic test is always
quoted as one reason that molecular diagnosis
is not yet offered to large populations, but
since the test is only performed once in a
lifetime and unlimited relatives can then be
identified at low cost, the health benefits are
considered by some countries, including the
Netherlands and some provinces of Spain,
greater than the cost of the test itself (12, 13). It is
important to note that the cost of the genetic
test is comparable to the cost of nuclear
magnetic resonance (NMR), an exam that is
routinely prescribed for different diseases and
usually more than once in a lifetime and does
not usually improve the patient’s prognosis as
the genetic test for FH does.
The Portuguese FH Study has been
successfully implemented since 1999 and has
already genetically identified 404 individuals
(171 index patients and 233 relatives) among
more than one thousand individuals sent for
study. A total of 78 different mutations in the
mutation in the LDLR gene. For diagnostic
purposes pre-treatment cholesterol values
are the most important, and so for this
analysis only cholesterol values of 333
index patients and 289 possible FH
relatives were used, since only these
patients knew their lipid values before
treatment. Since most FH patients have a
mutation in the LDLR gene, only patients
with a mutation in this gene were analyzed
in this study.
All data were analyzed using SPSS
software (version 17.0).  The t-test was used to
test for the difference between means. When
this could not be used a non-parametric test
was used (Mann-Whitney).
For all tests p<0.05 was considered sta-
tistically significant. 
RESULTS 
To date, 482 index patients and 858 relatives
(hypercholesterolemic and normolipidemic
individuals) have been sent to the Portuguese
FH Study. From these, 359 index patients have
their study of the LDLR, apoB and PCSK9 gene
completed as described elsewhere (14, 15) and the
others are under study. The characterization of
the 696 possible FH patients presented in this
study is represented in Table I. 
Clinical versus molecular diagnosis
To analyze the usefulness of molecular
diagnosis, graphs of total and LDL cholesterol
values by age were constructed for 622 possible
FH patients. The data are shown separately for
female propositi (index cases and hypercholes-
terolemic relatives), both with and without a
detectable mutation in the LDLR gene, and for
male propositi (Figure 1). Statistical analysis
revealed that there are significant differences
between total cholesterol (p<0.001) and apoB
(p=0.026) values in the group of children (male
and female) with and without a mutation in
LDLR. For female children LDL values were
also significantly different (p<0.001) between
subgroups, but for male children this difference
did not reach statistical significance. In adult
women there is a statistically significant
difference for total cholesterol (p=0.049), LDL
cholesterol (p=0.031), and apoB (p=0.003) in
the subgroups with and without an LDLR
mutation. In adult males there is a statistical
difference for total cholesterol (p=0.002). LDL
cholesterol (p=0.003), and apoB (p=0.023) in
subgroups with and without an LDLR mutation.
Nevertheless there was considerable dispersion
of values and it is not possible to distinguish
individually between patients with and without
a mutation in the LDLR gene, based only on
lipid profile.  
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n Pediatric group n Adult 
group
Age (years) 208 9.84±3.63 488 44.63±13.90
Female (%) 99 47.1 277 56.8
Male (%) 109 52.4 211 43.2
TC (mg/dL) 205 273.99±62.69 417 338.18±69.81
LDL (mg/dL) 174 201.93±60.31 300 250.92±72.19
HDL (mg/dL) 81 54.46±15.40 247 54.57±17.98
TG (mg/dL) 82 131.25±85.39 241 128.63±72.83
apoB (mg/dL) 144 110.29±39.00 124 155.36±49.19
apoAI (mg/dL) 144 144.15±33.33 128 151.84±32.65
Tendon Xanthomas (%) 208 0.0 488 2.5
CHD (%) 208 0.5 488 16.3
Under medication (%) 208 20.2 488 60.5
Table 1. Clinical and biochemical characterization of 696 possible FH patients presented in the study. Only pre-treatment values were
considered.
Clinical applicability of molecular
diagnosis
From the above results we can assume that
FH patients can only be correctly identified
when molecular diagnosis is performed. Since
the early identification of FH patients is
important to determine the therapeutic regime
for each patient, and it has been shown that
only molecular diagnosis can correctly
identify FH patients, the lipid profile of
patients genetically identified as having FH,
before and under medication (with a statin and
with a statin and ezetimibe) were analyzed to
assess whether these patients were receiving
appropriate treatment (Figure 2). As can be
seen in Table I, only 60.5% of the adult
patients are receiving any kind of treatment,
namely 81% index cases and 42.3% of the
relatives. It can be seen in Figure 2 that mean
total cholesterol and LDL cholesterol values
under treatment are above the limits
recommended by the European Cardiology
Society, especially in patients under treatment
with a statin alone. Of these, only 3.3% had
total cholesterol levels (2.2% for LDL-C)
below the recommendations for the general
population, and only 2.9% reached the target
for total cholesterol (0.8% for LDL-C)
recommended for high-risk patients. These
results were not considered strange since from
analysis of the clinical questionnaires, most
FH patients are being treated with low statin
doses. Only a small percentage of patients are
receiving combined therapy, and even in this
group only 9.8% have reached the target. In
the group of patients taking a statin alone, 913
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Figure 1. Clinical versus molecular diagnosis. a) Total cholesterol vs. age in females (index and relatives, with and without mutation); b)
Total cholesterol vs. age in males (index and relatives, with and without mutation); c) LDL cholesterol (LDL-C) vs. age in females (index
and relatives, with and without mutation); d) LDL cholesterol vs. age in males (index and relatives, with and without mutation).
Age (years) Age (years)
Age (years) Age (years)
total cholesterol levels decreased by only 20%
and LDL cholesterol by only 23%. In patients
taking a statin and ezetimibe total cholesterol
decreased in 32% and LDL cholesterol in 40%.
These results could be improved if a potent
statin were prescribed to all these patients,
instead of a low dose of a first-generation statin,
as is currently recommended by the
international experts on FH management (5, 6).
These results show that most FH patients have
not complied with the recommendations of the
European Cardiology Society or of NICE for FH
patients. These numbers also show that these
FH patients are not being treated as having a
genetic disorder, making molecular diagnosis
even more important as a cardiovascular risk
stratification tool. 
Molecular diagnosis and patient prognosis
In order to illustrate the subject, below we
present four clinical cases that well exemplify
the impact that molecular diagnosis can have
on patient prognosis and attitude towards the
severity of the disease.
Clinical case 1
Patient 1 is a 58-year-old man, with multiple
risk factors for cardiovascular disease:
dyslipidemia, smoking (60 pack/years), physical
inactivity, overweight (BMI=28) and family
history of premature coronary disease, as well
alcohol consumption (60 g/day). He has a
history of inferior myocardial infarction at age
38, non-ST-elevation myocardial infarction at
age 42 and coronary arterial bypass graft at
age 43 years (triple bypass). In spite of his
clinical history, the patient did not comply
with the lifestyle change measures and
therapeutic approach proposed. At age 49 the
patient returned to the hospital’s cardiology
out-patient clinic, with complaints of Canadian
Cardiology Society class II angina. The patient
repeated cardiac catheterization that
highlighted progression of the disease, and an
angioplasty of one of the bypasses was
required. His lipid profile was the following:
total cholesterol, 327 mg/dL; LDL cholesterol,
216 mg/dL; HDL cholesterol, 48 mg/dL; apoAI,
110 mg/dL; apoB, 240 mg/dL; Lp(a)  108
mg/dL; and triglycerides 313 mg/dl. Given his
personal and family history of dyslipidemia and
premature coronary disease, this patient was
enrolled in the Portuguese FH Study. The
genetic study showed the existence of a
mutation in exon 9 of the LDLR gene
(p.Ala431Thr, formerly A410T) (15). The family
study was performed and it was confirmed that
the mutation co-segregated in family members
who are hypercholesterolemic (Figure 3A).
After discovering he had a genetic disorder914
Rev Port Cardiol 
Vol. 29 Junho 10 / June 10
Figure 2. Comparison of patients without medication and taking statins and ezetimibe.
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and understanding his cardiovascular risk, the
patient expressed concern about his daughter,
who had inherited his mutation. For both,
index patient and daughter, the cardiologist
prescribed a moderate dose of a potent statin.
At present, the index patient and his daughter
are complying with the lifestyle measures and
prescribed pharmacological therapy, and are
clinically asymptomatic. 
Clinical case 2
Patient 2 is a 39-year-old woman followed at
the lipid clinic since 1997 due to refractory
hypercholesterolemia. Since her father was also
hypercholesterolemic (Figure 3B), she was
enrolled in the Portuguese F Study in 2001.
Her lipid profile at the time was the
following: total cholesterol 490 mg/dL; LDL
cholesterol 435 mg/dL; HDL cholesterol 42
mg/dL; apoAI 117 mg/dL; apoB 245 mg/dL
and Lp(a)  100 mg/dL; triglycerides within the
normal range. The molecular study revealed
that the patient was compound heterozygous,
with two distinct mutations (p.Ala431Thr,
formerly A410T, and c.313+6C/T), each in a
different allele.
After these results were sent to her
cardiologist, an extensive range of exams were
performed. Clinical studies including ECG,
echocardiogram, ECG exercise testing and
Achilles tendon ultrasonography were
performed and were normal. Carotid and
Figure 3. Pedigrees of clinical cases. (A) Clinical case 1. The arrow indicates the index patient; half-filled black symbols represent
individuals heterozygous for the mutation p.Ala431Thr; Nor, individuals in whom the family mutation was not found. (B) Clinical case
2. The arrow indicates the index patient; half-filled black symbols represent individuals heterozygous for the mutation p.Ala431Thr; half-
filled gray symbols represent individuals heterozygous for the mutation c.313+6 C>T; Nor, individuals where the family mutation was
not found. (C) Clinical case 3. The arrow indicates the index patient; half-filled black symbols represent individuals heterozygous for the
mutation c.190+4insTG; Nor, individuals in whom the family mutation was not found. (D) Clinical case 4. The arrow indicates index
patient; half-filled black symbols represent individuals heterozygous for the mutation c.1359-5C>G; Nor, individuals in whom the family
mutation was not found. Below each symbol are generation numbers followed by age and pre-treatment total cholesterol levels in mg/dL.
Abbreviations: †, deceased; MI, myocardial infarction; TC, total cholesterol.
femoral arteries were studied with duplex
ultrasonography and intimal-medial thickness
(IMT) evaluated. IMT was normal in the
primitive carotid arteries and increased in the
common femoral artery. The clinical
phenotype presented by this patient is not that
described for homozygous FH patients,
nevertheless the molecular diagnosis
indicates why this patient did not respond to
any treatment available at the time. Due to her
molecular diagnosis, LDL apheresis was
initiated, but since she had to travel 200 km
twice a month for the treatment, was in
employment and had to take care of two
children, this was not practical. The
cardiologist then prescribed a moderate dose
of a potent statin and 10 mg of ezetimibe; the
patient has begun to respond to treatment, her
lipid profile at present being as follows: total
cholesterol, 251 mg/dL; LDL cholesterol, 181
mg/dL; HDL cholesterol, 50 mg/dL; apoAI
164 mg/dL; apoB 125 mg/dL and Lp(a)  98
mg/dL; triglycerides within normal range.
This molecular finding reveals that many
individuals are probably being under-
diagnosed; many individuals at risk are not
being correctly identified and have an even
greater risk of developing premature CHD.
Since this patient has been followed for many
years by her cardiologist, who is aware of her
increased cardiovascular risk, it is probable
that, if she continues to take the medication,
she will not suffer premature heart disease. 
Clinical case 3
Patient 3 is a woman who at 40 years of age
sought the advice of a medical geneticist  with
concerns about her health due to a strong
family history of premature CHD, in some
cases fatal. Her mother had a myocardial
infarction at age 40 and triple coronary
bypass/CAGB at age 52, and the family history
revealed several premature deaths in maternal
uncles (myocardial infarction in individuals
between 29-40 years old) (Figure 3C).
Even though the patient had been informed
that she had  high cholesterol levels, she was
never advised to take medication until the
present consultation.
The lipid profile, at the time of her
consultation, was the following: total
cholesterol, 354 mg/dL; LDL cholesterol, 211
mg/dL; HDL cholesterol, 37 mg/dL; apoAI 112
mg/dL; apoB 109 mg/dL and Lp(a)  82 mg/dL;
triglyceride levels within normal ranges.
Echocardiogram and carotid ultrasound with
intima-media complex measurement were
normal. Physical examination showed no
evidence of xanthomas or xanthelasma. The
patient was enrolled in the Portuguese FH
Study, which revealed the presence of the
c.190+4insTG mutation at the 5’ end of intron 2
of the LDLR gene. This insertion led to
retention of two nucleotides of intron 2. This
alteration creates a premature stop codon and
consequently a truncated LDLR protein of 206
amino acids that is not functional (14). Other
family members were asked to perform the
genetic test to confirm their hyperchole-
sterolemia due to an LDLR mutation but not all
agreed, even when the benefits were explained
of early detection of a genetic disease that is
treatable and, when patients receive the correct
treatment the progression of CHD can be slowed
or even stopped.
After confirmation by molecular analysis
that the patient had FH, and the mutation
encountered was predicted to produced a
severe phenotype, she was placed on a strict
diet with reduced fat and cholesterol intake
and daily exercise in addition to lipid-
-lowering therapy of a moderate dose of statin,
ezetimibe and acid acetylsalicylic. After 12
months of treatment, total cholesterol levels
had decreased to 184 mg/dL; LDL cholesterol,
124 mg/dL; HDL cholesterol, 76 mg/dL; and
triglyceride levels were within normal ranges.
The patient was encouraged to maintain the
lifestyle and treatment prescribed.  If she
does, her cardiovascular risk can be reduced
substantially and she will most probably not
develop premature CHD like many members
of her family, since at present she shows no
evidence of atherosclerotic disease.
Clinical case 4
Patient 4 is a 55-year-old woman with a
clinical diagnosis of familial hypercholes-916
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terolemia, presenting a strong family history of
CHD: her mother had a myocardial infarction at
65 years of age and her maternal aunt had a
severe stroke at age 52 (Figure 3D). The patient
was aware of her condition since she was 35
years old and had been treated with different
statins but had never reached the target values.
On her own initiative, she sought the advice of a
medical geneticist due to her family history of
premature cardiovascular disease and because
she was aware of the difficulty of treating her
hypercholesterolemia.
At 50 years of age, under treatment with a
first-generation statin, her lipid profile was
the following: total cholesterol 265 mg/dL;
LDL cholesterol 183 mg/dL; HDL cholesterol
70 mg/dl; and triglyceride levels were within
normal ranges. Echocardiogram and carotid
ultrasound with intima-media complex
measurement were normal. Physical
examination showed no evidence of
xanthomas or xanthelasma. She was enrolled
at the time in the Portuguese FH Study, and a
splicing mutation in the LDLR gene was found
that co-segregated in the family with
hypercholesterolemia, except in a brother with
hypertriglyceridemia and hypercholesterolemia,
overweight and with “social” alcohol
consumption (Figure 3D). The mutation found
is the c.1359-5C>G substitution, leading to
retention of intron 9. RNA studies show that
this alteration is predicted to result in a
protein with two additional incorrect amino
acid residues after those encoded by exon 9
followed by a stop codon and consequently a
non-functional truncated protein of 454 amino
acids (16). After ascertaining the severity of
the mutation that the patient carried, the
clinician prescribed a diet with restricted fat
intake, daily exercise and walking, a moderate
dose of a potent statin, ezetimibe and
ezetimibe and acid acetylsalicylic. After 12
months of treatment, total cholesterol
decreased to 144 mg/dL, LDL cholesterol to
87 mg/dL, HDL cholesterol to 87 mg/dL and
triglyceride levels were within normal ranges.
Since total cholesterol values had decreased
more than sufficiently, the statin dose was
adjusted to decrease possible secondary
effects. Again, if the patient maintains the
medication and lifestyle advice, her
cardiovascular risk will reduce substantially.
DISCUSSION
Clinical versus molecular diagnosis
To identify a patient as having FH can be
straightforward when, for example, the patient
has severe hypercholesterolemia, presents
tendon xanthomas, already has premature heart
disease and also has a family history of
hypercholesterolemia and premature heart
disease in relatives.  However, the majority of
Portuguese FH patients do not present all these
clinical characteristics and in these cases
clinical diagnosis can be difficult. Even when
an index patient is identified as having
inherited hypercholesterolemia based on
convincing clinical criteria, it is doubtful
whether all relatives at risk can also be
identified by clinical criteria alone. Frequently,
some of these relatives, especially if they are
young, can have borderline cholesterol values
and may not show other clinical signs, which
will prevent a diagnosis of FH based solely on
clinical evidence. On the other hand, some
individuals may have increased cholesterol due
to environmental factors and can be
misdiagnosed as having FH. In these cases
molecular diagnosis can be useful. Figure 1
clearly illustrates these situations. The total
cholesterol and LDL values in the two groups
analyzed are significantly different but the
figures show that it is difficult to distinguish
between patients with and without a mutation
in the LDLR gene based only on clinical
evidence. However, penetrance is high, with
virtually all mutation carriers having total
cholesterol and LDL cholesterol levels well
above the recommended levels for the normal
population. At adult age several factors can
influence cholesterol values, and only genetic
testing can give an accurate diagnosis of the
origin of the hypercholesterolemia. In children
it can be argued that environmental factors
will not have had time to play a role in the
development of hypercholesterolemia, and so 917
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what is seen is a true phenotype, which in
some cases can be used to guess the genotype.
Nevertheless, even when a statistical
difference is observed, the information this
adds may be limited. From the graphic
analysis it can be seen that the values overlap
in these two groups, making it difficult to
distinguish between individuals with and
without the mutation. The fact that about 40%
of children in the Portuguese FH Study do not
have a mutation in the LDLR gene confirms
that clinical data alone are not sufficient to
determine the cause of the hypercholes-
terolemia, even in children (14, 15). 
In a study in Denmark (16), 76% of mutation
carrier relatives had LDL-C levels above the
90th percentile, although 15% of non-
mutation carrier relatives also had levels
above this cut-off. However, this means that a
simple LDL-C measure will not distinguish
adequately between mutation carriers and
non-carriers. Data from the Dutch data set of
over 2000 mutation-positive and negative FH
relatives demonstrates that this overlap
increases with age, due to the general increase
in LDL-C levels seen in normal people as they
age, such that by the age of 45-55 years, the
false negative rate using the inflection
between the LDL-C distribution in mutation
carriers and non-carriers is ~45%. The
conclusion from these data is that when a
relative has inherited an FH-causing
mutation, the penetrance is 100%, although
other relatives who have not inherited the
family mutation may also have elevated LDL-
C for polygenic or environmental reasons (e.g.
a poor diet) (17).
One of the questions that this work aimed
to address was whether molecular diagnosis is
indeed necessary to properly assess the CHD
risk of a patient already diagnosed with
hypercholesterolemia. Evidence has shown
that even for a hypercholesterolemic adult
who already attends a lipid clinic and is
receiving cholesterol-lowering medication,
molecular diagnosis can focus more attention
on the aggressiveness of the medication, since
most patients do not reach the desired targets.
Individuals with inherited hypercholes-
terolemia need more effective treatment than
those who only become hypercholesterolemic
in middle age, since they have been
accumulating cholesterol since birth. Another
benefit of molecular diagnosis is the early
identification of patients and relatives at high
risk of developing CHD, especially children
and adolescents whose hypercholesterolemia
may otherwise be identified much later in life,
sometimes only when the first cardiovascular
problems appear. If these children are
identified early in life preventive inter-
ventions can be made to change lifestyle (and
initiate therapy when advisable) to decrease
the elevated cardiovascular risk of these
children. It is well known that a lifelong
change to target cholesterol levels can
dramatically reduce the cardiovascular risk of
the general population (18) and this also applies
to these patients. 
Molecular diagnosis for FH - Applicability
to clinical practice
FH fulfils the World Health Organization
criteria for screening programs (10). Since the
introduction of statins (HMG-CoA reductase
inhibitors) in the last decade, the prognosis of
FH patients has improved substantially and
therefore it is considered appropriate to
perform systematic screening for FH (20).  Some
countries, such as the UK (21) (22) and the
Netherlands (23, 24), have established a
specialized genetic service for FH and in
recent years a cascade screening program for
FH has begun.  The LDLR gene has been
extensively studied and the regions where
mutations are most common are now known, and
so a strategy can be designed.  During recent
years the technology has also improved
immensely and new methods, such as denaturing
high-performance liquid chromatography
(DHPLC) and heteroduplex analysis by
capillary electrophoresis (25), have proved to be
less time-consuming and more cost-effective
than other methods and can be used
successfully to screen for mutations in the
LDL receptor gene. Studies in the cost-
effectiveness of performing genetic analysis
for FH indicates that screening of 16-year-old918
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adolescents is the most cost-effective case-
finding strategy, followed by family tracing
and screening of patients admitted to hospital
with premature myocardial infarction (20, 26). 
Information on the pathogenicity of each
mutation from functional assays is also
important to identify patients at an even
higher risk of developing CHD and to stratify
their cardiovascular risk. 
In general, molecular diagnosis of FH is
feasible and can be obtained in 1-2 months if
the correct technology is available. In Portu-
gal the test will be offered to the population by
our Institute at a cost of about 500 euros, like
many other genetic tests or exams such as
NMR. 
Other authors argue that it is cost-effective
to identify FH patients through molecular
diagnosis, especially those identified by
cascade screening once the index case is
analyzed. The London IDEAS FH cascade
audit project examined the cost of finding and
testing an index case. The average cost was
£500 (with a range of £330-£2,470 between
clinics). Based on their findings and the
national FH screening program in the
Netherlands, they concluded that cascade
testing for FH was highly cost-effective, with
an estimated cost of US$8,700 per life year
gained (discounted) and so well below the
£20,000 per QUALY used by NICE as a
benchmark for cost-effectiveness (27).
Ethical issues related to performing a
genetic test for a disease are usually more
problematic if a treatment for that disease
does not exist and so no benefits can be
derived from an early diagnosis. FH is a
disease for which, fortunately, effective
treatment exists and can be offered to
patients, thus improving their health and
quality of life. The sooner the disorder is
diagnosed the better the patient’s prognosis.
Nowadays, an FH patient correctly diagnosed
and treated at an early age may never have
CHD (28). At present, cardiovascular disease is
still the leading cause of death in developed
countries and the associated morbidity is also
substantial. So, in general, it can be said that
there are no negative ethical implications of
performing genetic testing for FH and, in fact,
it can be beneficial for the health of the
patient and in reducing the state’s treatment
burden and hospitalization costs associated
with cardiovascular events. In the case of FH,
it is thought that 75–90% of at-risk
individuals remain unaware of their risk. As
the penetrance of FH is very high,
intervention may be justified for a substantial
proportion of these people since, with potent
statins alone or in combination therapy, their
risk could be reduced to near the average
population risk for coronary heart disease.
CONCLUSIONS
The genetically identified FH patients
from the Portuguese FH Study are now
receiving counseling and treatment based on
their diagnosis, and it is expected that some,
especially younger individuals, will never
develop premature CHD due to the early
detection of their disease through molecular
diagnosis. Molecular study has thus helped to
improve patient prognosis. Molecular dia-
gnosis also helps to determine the appropriate
therapeutic regime for each patient and
functional assays identify patients at even
higher risk of developing CHD, stratifying the
cardiovascular risk for each patient. None of
the patients in whom no mutation was found in
the LDL receptor gene ceased their
medication, as this was not the aim of the
study, and the fact that no mutation was found
in this gene does not exclude the possibility of
hypercholesterolemia due to other gene
defects. Nonetheless, several patients saw
their medication changed to a more effective
therapeutic regime due to a mutation being
found in their LDLR gene. Clinicians also
stated that patients who were usually lax about
taking their medication, after obtaining a
molecular diagnosis, understood better that
they had a chronic disorder that needed
chronic treatment and made an effort not to
forget to take the medication. 
Unfortunately there are social and economic
limitations that lead to patients to givegiving up 919
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their medication at some point in their
treatment, and about which scientists and
clinicians can do nothing. The state
contribution to the expensive medication for
FH, such as statins and ezetimibe, is only 40%
compared to medication for other chronic or
molecular disorders such as diabetes mellitus
or cystic fibrosis, for which, in most cases, the
costs are almost 100% covered by the state. In
Spain, due to the intervention of scientists and
clinicians working together with interested
politicians, the government decided that FH
patients would have all medication they
needed, paying only a small fee per month.
They presented calculations that it was more
cost-effective to identify and treat these patients
at an early age (thus preventing coronary events)
than to perform angioplasty or heart surgery
later in life(27).
A last consideration is that clinicians,
especially pediatric cardiologists, pediatricians,
cardiologists, nephrologists, endocrinologists,
internists, general physicians and medical
geneticists, should  all be aware of the benefits
of the early identification of these patients and
make use of molecular diagnosis to correctly
920
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identify the cause of hypercholesterolemia
presented by their patients and to assess and
treat their cardiovascular risk.
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